Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Michael Walter

Michael Walter
Managing Editor


Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

LATEST ARTICLES BY THIS AUTHOR

AI delivers helpful heart health advice—but not every time
Mavacamten fails to boost outcomes for patients with nonobstructive HCM
U.S. considering new tariffs for heart valves, imaging equipment and other medical devices
CVD responsible for 1 in 3 deaths around the world
How TAVR device type may impact outcomes in patients with excessive cusp calcification
A call to action for pediatric cardiologists: CVD prevention begins at childhood
TAVR reinterventions: What new data tell us about redo, explant trends over time
Semaglutide tops dulaglutide when treating patients with type 2 diabetes and CVD
American College of Cardiology shares new expert recommendations on treating tricuspid regurgitation
FDA investigating Johnson & Johnson medical devices again after 5 injuries

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page …63
    • Page 64
    • Page 65
    • Page 66
    • Current page 67
    • Page 68
    • Page 69
    • Page 70
    • Page 71 …
    • Next page Next ›
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme